22nd Annual General Meeting of Krka, d. d., Novo mesto

In addition to other business, shareholders deliberated on the allocation of accumulated profit for 2015, deciding to pay a gross dividend of €2.65 per share, which is an increase by 6% from last year. They also elected a new SB member, Dr Boris Žnidarič, his term-in-office having commenced as at the day of election at the AGM.

Krka’s President of the Management Board and Chief Executive Jože Colarič opened the AGM by presenting Krka’s operations highlights for 2015 and some of the Group’s already known operating results for the first half of 2016.

Krka Group operations in the first half of 2016

Krka Group sales by Region
The Krka Group sold €603.8 million worth of products and services in the first half of 2016, up €4 million or 1% compared to the first half of last year. Sales in markets outside Slovenia totalled €562.6 million, which represents over 93% of the Group’s total sales. Production and sales volumes in the first half of 2016 increased by 12% from the same period last year.

The highest relative as well as absolute growth, of 27%, or €16.3 million, was recorded in Region South-East Europe, where sales totalled €76.8 million, which represents 12.7% of Group sales. Sales in the domestic market were up 6% to €41.2 million, which represents 6.8% of Group sales. In Region Overseas Markets six-month product sales totalled €18.5 million (25% increase), which represents 3.1% of Group sales. Krka’s largest sales region was Region East Europe, where sales totalled €175.5 million, which represents 29.1% of Group sales and a year-on-year decrease by 6%. The second largest region in terms of sales was Region West Europe, where Krka generated €150.4 million of sales (down 8%), which represents 24.9% of Group sales. Product sales in Region Central Europe represented 23.4% of Group sales and amounted to €141.4 million, up 3%.

Krka Group sales by product and service group
The Krka Group sold €499.4 million worth of prescription pharmaceuticals, down 2% compared to the same period last year. Prescription pharmaceuticals represent 82.7% of Group sales. Non-prescription product sales were down 1% compared to the same period last year, to €50.3 million (8.3% of Group sales). The sales of animal health products were up 44% to €37.3 million, which is 6.2% of Group sales. Health resort and tourist services totalled €15.4 million in revenues, up 10% from the same period last year (2.6% of Group sales), and other revenues amounted to €1.3 million (0.2% of Group sales).

More information in press release.